BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price boosted by research analysts at JPMorgan Chase & Co. from $86.00 to $87.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 55.77% from the company’s current price.

Several other research analysts have also recently commented on the stock. Citigroup upped their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Raymond James Financial upgraded BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 target price on the stock in a report on Monday, October 12th. Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th. Finally, William Blair raised BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $88.68.

BioMarin Pharmaceutical Stock Performance

BMRN traded up $1.18 during trading on Tuesday, reaching $55.85. 478,293 shares of the company were exchanged, compared to its average volume of 2,085,081. The stock has a market cap of $10.81 billion, a P/E ratio of 151.04, a PEG ratio of 0.38 and a beta of 0.22. The firm has a 50 day moving average of $62.73 and a 200 day moving average of $58.67. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period last year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts forecast that BioMarin Pharmaceutical will post 4.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Primecap Management Co. CA purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter worth about $811,962,000. Dimensional Fund Advisors LP boosted its position in BioMarin Pharmaceutical by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock worth $214,804,000 after acquiring an additional 481,176 shares during the period. Assenagon Asset Management S.A. boosted its position in BioMarin Pharmaceutical by 35.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,920,658 shares of the biotechnology company’s stock worth $108,498,000 after acquiring an additional 501,591 shares during the period. First Trust Advisors LP grew its stake in BioMarin Pharmaceutical by 43.3% during the 1st quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company’s stock valued at $94,479,000 after acquiring an additional 505,692 shares in the last quarter. Finally, Caisse de depot et placement du Quebec purchased a new position in BioMarin Pharmaceutical during the 2nd quarter valued at about $70,749,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.